Skip to content

Application of botulinum toxin tapy A to treat the spasticity of lower extremities in patients with ALS

Application of botulinum toxin tapy A to treat the spasticity of lower extremities in patients with ALS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061794
Enrollment
Unknown
Registered
2022-07-02
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amyotrophic lateral sclerosis

Interventions

the treatment group:Botulinum toxin An injection therapy

Sponsors

The People's Hospital of China Three Gorges University.The First People's Hospital of Yichang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. diagnosis of possible or definite ALS according to the revised ElEscorial criteria. 2. using the Medical Research Council (MRC) scale to assess the target muscle strength MRC >= 4, and the gait impaired but still standing (with the highest lower limb score of 8 in the total ALSFRS-R score). 3. using the modified Ashworth score (mAs) to evaluate moderate to severe lower limb spasm (LL) mAs >= 2, and gait interference with ankle clonus or Achilles tendon contracture. 4. the mild disease progression rate (?FS), measured as ?FS1= (48-ALSFRS-R at recruitment)\ duration from onset to injection (month) < 0.5.

Exclusion criteria

Exclusion criteria: 1. other diseases with spasms (such as stroke, Parkinson's, etc.). 2. according to the ultrasonic evaluation, there was no fibrous degeneration in the spastic muscle, so it was not suitable for botulinum toxin A injection. 3. stop taking oral antispasmodic drugs for less than one month, or are using other drugs that act on neuromuscular junctions (such as quinine, aminoglycoside antibiotics, azithromycin, morphine, etc.). 4. FVC 4 years, age less than 18 years or more than 70 years old. 6. bulbar involvement such as dyspnea or dysphagia. 7. those who are allergic to botulinum toxin An or refuse to sign an informed consent form for botulinum toxin A injection treatment.

Design outcomes

Primary

MeasureTime frame
CSS;10WMT;

Secondary

MeasureTime frame
Barthel scale;the mild disease progression rate (?FS);

Countries

China

Contacts

Public ContactYunhong Zha

The People's Hospital of China Three Gorges University/ The First People's Hospital of Yichang

yha7808@ctgu.edu.cn+86 13872662508

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026